Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
death D28 | 0.60 [0.45, 0.79] | | < 1 | | 0% | 12 studies (12/-) | 100.0 % | some concern | low | moderate | crucial | - |
death or transfer to ICU | 0.70 [0.44, 1.12] | | < 1 | | 0% | 1 study (1/-) | 93.1 % | NA | not evaluable | | crucial | - |
deaths | 0.73 [0.62, 0.86] | | < 1 | | 0% | 31 studies (31/-) | 100.0 % | some concern | critical | moderate | crucial | - |
deaths (time to event analysis only) | 0.68 [0.43, 1.08] | | < 1 | | 0% | 4 studies (4/-) | 95.0 % | some concern | not evaluable | moderate | crucial | - |
clinical deterioration | 0.69 [0.47, 1.00] | | < 1 | | 72% | 13 studies (13/-) | 97.4 % | some concern | low | moderate | important | - |
clinical improvement | 1.30 [1.04, 1.62] | | > 1 | | 66% | 14 studies (14/-) | 98.9 % | some concern | low | moderate | important | - |
clinical improvement (14-day) | 1.22 [1.00, 1.49] | | > 1 | | 32% | 10 studies (10/-) | 97.6 % | some concern | low | moderate | important | - |
clinical improvement (21-day) | 2.09 [0.04, 119.96] | | > 1 | | 0% | 1 study (1/-) | 63.7 % | NA | not evaluable | | important | - |
clinical improvement (28-day) | 1.34 [1.10, 1.62] | | > 1 | | 46% | 5 studies (5/-) | 99.8 % | some concern | serious | moderate | important | - |
clinical improvement (7-day) | 1.32 [1.05, 1.67] | | > 1 | | 69% | 9 studies (9/-) | 99.0 % | some concern | serious | moderate | important | - |
clinical improvement (time to event analysis only) | 1.22 [1.01, 1.49] | | > 1 | | 73% | 10 studies (10/-) | 97.8 % | some concern | critical | moderate | important | - |
death or ventilation | 0.75 [0.63, 0.88] | | < 1 | | 0% | 5 studies (5/-) | 100.0 % | some concern | not evaluable | moderate | important | - |
hospital discharge | 1.25 [0.92, 1.70] | | > 1 | | 56% | 5 studies (5/-) | 92.7 % | some concern | not evaluable | moderate | important | - |
hospitalization | 1.00 [0.14, 7.34] | | < 1 | | 0% | 1 study (1/-) | 50.0 % | NA | not evaluable | | important | - |
mechanical ventilation | 0.90 [0.59, 1.37] | | < 1 | | 37% | 13 studies (13/-) | 68.8 % | some concern | critical | moderate | important | - |
mechanical ventilation (time to event analysis only) | 0.06 [0.01, 0.83] | | < 1 | | 0% | 1 study (1/-) | 98.2 % | NA | not evaluable | | important | - |
radiologic improvement (14-day) | 1.82 [0.95, 3.51] | | > 1 | | 39% | 4 studies (4/-) | 96.4 % | some concern | not evaluable | moderate | important | - |
radiologic improvement (7-day) | 0.53 [0.02, 17.19] | | > 1 | | 74% | 3 studies (3/-) | 36.2 % | some concern | not evaluable | moderate | important | - |
viral clearance | 1.74 [1.25, 2.42] | | > 1 | | 73% | 14 studies (14/-) | 100.0 % | some concern | critical | moderate | important | - |
viral clearance (time to event analysis only) | 1.39 [0.88, 2.20] | | > 1 | | 78% | 4 studies (4/-) | 92.1 % | some concern | not evaluable | moderate | important | - |
viral clearance by day 14 | 0.89 [0.14, 5.54] | | > 1 | | 94% | 8 studies (8/-) | 44.9 % | some concern | not evaluable | moderate | important | - |
viral clearance by day 7 | 1.24 [0.96, 1.61] | | > 1 | | 57% | 12 studies (12/-) | 94.8 % | some concern | low | moderate | important | - |
ICU admission | 0.98 [0.74, 1.29] | | < 1 | | 0% | 8 studies (8/-) | 56.2 % | some concern | not evaluable | moderate | non important | - |
recovery | 1.01 [0.82, 1.25] | | > 1 | | 56% | 4 studies (4/-) | 54.1 % | some concern | not evaluable | moderate | non important | - |
severe COVID-19 occurrence | 0.30 [0.07, 1.27] | | < 1 | | 0% | 1 study (1/-) | 94.9 % | NA | not evaluable | | non important | - |
safety endpoints 00 |
serious adverse events | 0.74 [0.53, 1.03] | | < 1 | | 0% | 16 studies (16/-) | 96.4 % | some concern | critical | moderate | important | - |
acute kidney injury | 1.18 [0.44, 3.18] | | < 1 | | 0% | 1 study (1/-) | 37.2 % | NA | not evaluable | | non important | - |
adverse events | 1.83 [1.30, 2.59] | | < 1 | | 69% | 17 studies (17/-) | 0.0 % | some concern | low | moderate | non important | - |
arrhythmia | 2.24 [0.23, 21.69] | | < 1 | | 0% | 1 study (1/-) | 24.5 % | NA | not evaluable | | non important | - |
elevated liver enzymes | 3.48 [1.40, 8.64] | | < 1 | | 0% | 1 study (1/-) | 0.4 % | NA | not evaluable | | non important | - |
long QT | 9.79 [1.27, 75.50] | | < 1 | | 0% | 1 study (1/-) | 1.5 % | NA | not evaluable | | non important | - |
Major bleeding | 1.80 [0.88, 3.67] | | < 1 | | 0% | 1 study (1/-) | 5.3 % | NA | not evaluable | | non important | - |
renal impairment | 1.35 [0.47, 3.86] | | < 1 | | 0% | 1 study (1/-) | 28.8 % | NA | not evaluable | | non important | - |
serious adverse events (SAE), any | 0.50 [0.32, 0.79] | | < 1 | | 0% | 1 study (1/-) | 99.9 % | NA | not evaluable | | non important | - |
AE of interest endpoints 00 |
Thromboembolic events | 0.89 [0.31, 2.55] | | < 1 | | 0% | 1 study (1/-) | 58.6 % | NA | not evaluable | | non important | - |